NR3C2 and hydrops fetalis: Utilisation and optimisation of HF guideline‐directed medical therapies (GMDTs) (i.e. renin‐angiotensin system inhibitors (RASIs), HF‐specific beta‐blockers, mineralocorticoid receptor antagonists (MRAs) and, more recently, sodium‐glucose co‐transporter‐2 inhibitors (SGLT2‐i)) have demonstrated reduced mortality and hospitalisation.4